GlassScriptPhysician profile
Robin Rachel Bunn
NPI 1700364023
$2,297.99
in general payments reported to CMS, 2019-2025
26 companies · $91.60 in 2025
The $91.60 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $516 · 2022: $896 · 2023: $692 · 2024: $102 · 2025: $91.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $886.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $886.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $582.74 | 2021-2023 | |
| Glaxosmithkline, LLC. | $282.25 | 2022-2024 | Bexsero, Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $240.29 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $201.69 | 2021-2024 | Emgality, Jardiance, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.65 | 2021-2023 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $90.73 | 2022 | |
| Pfizer INC. | $89.81 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $76.88 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $64.04 | 2022-2024 | Vaxneuvance, Gardasil 9, M-M-R II |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.64 | 2021-2024 | Trulance, Xifaxan |
| Axsome Therapeutics, INC. | $53.00 | 2023-2024 | Auvelity |
| Exact Sciences Corporation | $47.85 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $44.48 | 2021 | |
| Abbott Laboratories | $37.76 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $35.78 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $34.82 | 2022-2023 | Farxiga |
| Kowa Pharmaceuticals America, INC. | $28.86 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $25.96 | 2025 | Rexulti |
| Ultragenyx Pharmaceutical INC. | $23.34 | 2021 | |
| Inspire Medical Systems, INC. | $18.43 | 2025 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $17.68 | 2022 | |
| Althera Pharmaceuticals LLC | $16.37 | 2021 | |
| Boston Scientific Corporation | $14.81 | 2024 | Watchman Access System |
| Dexcom, INC. | $14.49 | 2023 | Dexcom G6 Transmitter |
| Currax Pharmaceuticals LLC | $13.66 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Bunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.